GLOBUS MEDICAL INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that GLOBUS MEDICAL INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.94B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $2.52B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.57B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $1.02B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $958.10M | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | $233.45M | Feb 17, 2021 |
| FY2020 | Sep 30, 2020 | $216.10M | Feb 17, 2021 |
| FY2020 | Jun 30, 2020 | $148.92M | Feb 17, 2021 |
| FY2020 | Mar 31, 2020 | $190.58M | Feb 17, 2021 |
| FY2020 | Dec 31, 2019 | $211.67M | Feb 17, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $176.03M | Feb 22, 2018 |
| FY2017 | Sep 30, 2017 | $151.74M | Feb 22, 2018 |
| FY2017 | Jun 30, 2017 | $152.39M | Feb 22, 2018 |
| FY2017 | Mar 31, 2017 | $155.81M | Feb 22, 2018 |
| FY2017 | Dec 31, 2016 | $151.59M | Feb 22, 2018 |
| FY2017 | Sep 30, 2016 | $135.65M | Feb 22, 2018 |
| FY2017 | Jun 30, 2016 | $137.49M | Feb 22, 2018 |
| FY2017 | Mar 31, 2016 | $139.26M | Feb 22, 2018 |
| FY2016 | Dec 31, 2015 | $142.59M | Mar 16, 2017 |
| FY2016 | Sep 30, 2015 | $136.99M | Mar 16, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $1.02B | Feb 21, 2024 |
| FY2023 | Dec 31, 2022 | $759.12M | Feb 21, 2024 |
| FY2023 | Dec 31, 2021 | $718.88M | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | $172.59M | Feb 17, 2021 |
| FY2020 | Sep 30, 2020 | $159.00M | Feb 17, 2021 |
| FY2020 | Jun 30, 2020 | $98.28M | Feb 17, 2021 |
| FY2020 | Mar 31, 2020 | $141.71M | Feb 17, 2021 |
| FY2020 | Dec 31, 2019 | $162.91M | Feb 17, 2021 |
| FY2020 | Sep 30, 2019 | $150.83M | Feb 17, 2021 |
| FY2020 | Jun 30, 2019 | $150.55M | Feb 17, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $537.87M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $102.98M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $122.87M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $190.17M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $149.19M | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | $52.96M | Feb 17, 2021 |
| FY2020 | Sep 30, 2020 | $44.22M | Feb 17, 2021 |
| FY2020 | Jun 30, 2020 | ($20.84M) | Feb 17, 2021 |
| FY2020 | Mar 31, 2020 | $25.95M | Feb 17, 2021 |
| FY2020 | Dec 31, 2019 | $45.53M | Feb 17, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $479.82M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $165.99M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $133.14M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $227.95M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $171.95M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $111.43M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $171.99M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $169.33M | Feb 17, 2021 |
| FY2019 | Sep 30, 2018 | $169.33M | Feb 20, 2020 |
| FY2019 | Dec 31, 2017 | $161.84M | Mar 2, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $147.25M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $163.75M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $124.01M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $73.02M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $97.35M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $84.52M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $60.07M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $55.50M | Feb 17, 2021 |
| FY2019 | Sep 30, 2018 | $55.50M | Feb 20, 2020 |
| FY2019 | Dec 31, 2017 | $43.68M | Mar 2, 2020 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.18B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $981.36M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $643.84M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $432.12M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $408.15M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $354.76M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $354.76M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $311.59M | Feb 17, 2021 |
| FY2019 | Sep 30, 2018 | $311.59M | Feb 20, 2020 |
| FY2019 | Dec 31, 2017 | $267.82M | Mar 2, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $753.45M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $520.64M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $243.50M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $178.47M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $276.27M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $198.79M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $171.98M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $181.64M | Feb 17, 2021 |
| FY2019 | Sep 30, 2018 | $181.64M | Feb 20, 2020 |
| FY2019 | Dec 31, 2017 | $159.06M | Mar 2, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $164.68M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $115.43M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $78.27M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $74.05M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $56.90M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $63.66M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $70.75M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $59.70M | Feb 17, 2021 |
| FY2019 | Sep 30, 2018 | $59.70M | Feb 20, 2020 |
| FY2019 | Dec 31, 2017 | $51.30M | Mar 2, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.30B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $5.25B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $5.09B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $2.08B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.96B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $1.68B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.53B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $1.30B | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $1.08B | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $927.64M | Feb 22, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $729.51M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.07B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.09B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $229.75M | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $215.88M | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $173.19M | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $129.63M | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $115.15M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $110.72M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $95.56M | Feb 22, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.57B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.18B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $4.00B | Feb 24, 2026 |
| FY2025 | Dec 31, 2022 | $1.85B | Feb 24, 2026 |
| FY2022 | Sep 30, 2022 | $1.76B | Feb 21, 2023 |
| FY2022 | Jun 30, 2022 | $1.70B | Feb 21, 2023 |
| FY2022 | Mar 31, 2022 | $1.79B | Feb 21, 2023 |
| FY2024 | Dec 31, 2021 | $1.74B | Feb 20, 2025 |
| FY2022 | Sep 30, 2021 | $1.72B | Feb 21, 2023 |
| FY2022 | Jun 30, 2021 | $1.64B | Feb 21, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.44B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.43B | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $1.43B | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $197.47M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $179.71M | Feb 21, 2024 |
| FY2022 | Dec 31, 2020 | $156.72M | Feb 21, 2023 |
| FY2021 | Dec 31, 2019 | $128.78M | Feb 17, 2022 |
| FY2020 | Dec 31, 2018 | $123.73M | Feb 17, 2021 |
| FY2019 | Dec 31, 2017 | $123.89M | Mar 2, 2020 |
| FY2017 | Dec 31, 2016 | $105.93M | Feb 22, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.39B | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $1.15B | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $1.14B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.24B | Feb 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.19B | Feb 21, 2023 |
| FY2021 | Dec 31, 2020 | $1.05B | Feb 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.05B | Feb 17, 2021 |
| FY2019 | Dec 31, 2018 | $892.72M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | $736.25M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | $628.90M | Feb 22, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $526.16M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $784.44M | Feb 24, 2026 |
| FY2019 | Dec 31, 2019 | $195.47M | Mar 2, 2020 |
| FY2019 | Dec 31, 2018 | $139.65M | Mar 2, 2020 |
| FY2019 | Dec 31, 2017 | $118.82M | Mar 2, 2020 |
| FY2019 | Dec 31, 2016 | $66.95M | Mar 2, 2020 |
| FY2018 | Dec 31, 2015 | $57.65M | Feb 21, 2019 |
| FY2017 | Dec 31, 2014 | $82.27M | Feb 22, 2018 |
| FY2016 | Dec 31, 2013 | $89.96M | Mar 16, 2017 |
| FY2015 | Dec 31, 2012 | $212.40M | Feb 29, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 17, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 17, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 17, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 17, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 17, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | 1 | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 21, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 17, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 17, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 17, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 17, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 17, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | 99.83M | Mar 2, 2020 |
| FY2019 | Dec 31, 2018 | 98.57M | Mar 2, 2020 |
| FY2018 | Dec 31, 2017 | 96.66M | Feb 21, 2019 |
| FY2017 | Dec 31, 2016 | 95.93M | Feb 22, 2018 |
| FY2016 | Dec 31, 2015 | 95.32M | Mar 16, 2017 |
| FY2015 | Dec 31, 2014 | 94.71M | Feb 29, 2016 |
| FY2014 | Dec 31, 2013 | 93.44M | Feb 26, 2015 |
| FY2013 | Dec 31, 2012 | 91.27M | Mar 14, 2014 |
| FY2012 | Dec 31, 2011 | 72.53M | Jun 13, 2013 |